Brief: Innate Pharma FY Net Loss Widens To EUR 64 Million

Innate Pharma SA

18/03/2021 06:07

March 18 (Reuters) - Innate Pharma SA  IPH.PA :
    * REG-INNATE PHARMA REPORTS FULL YEAR 2020 FINANCIAL RESULTS AND BUSINESS
UPDATE
    * CASH POSITION OF EUR 190.6 MILLION(2) AS OF DECEMBER 31, 2020
    * AS OF DECEMBER 31, 2020, FINANCIAL LIABILITIES AMOUNT TO EUR 19.1M (EUR
18.7M AS
OF DECEMBER 31, 2019)
    * 2020 REVENUE AND OTHER INCOME AMOUNTED TO EUR 70.5M IN 2020 (2019: EUR
85.8M,
-17.9%)
    * 2020 OPERATING EXPENSES OF EUR 89.9M IN 2020 (2019: EUR 104.6M, -14.1%)
    * FY NET LOSS EUR 64.0 MILLION VERSUS LOSS EUR 20.8 MILLION YEAR AGO
    * FY OPERATING LOSS AFTER IMPAIRMENT EUR 62.1 MILLION VERSUS LOSS EUR 27.1
MILLION
YEAR AGO
    * LACUTAMAB RECEIVED PRIME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY IN
SEZARY SYNDROME; CLINICAL DEVELOPMENT PROGRAM ADVANCES IN MYCOSIS FUNGOIDES
AND PERIPHERAL T-CELL LYMPHOMA
    * COMPANY’S FIRST NK CELL ENGAGER SELECTED BY SANOFI AS DRUG CANDIDATE FOR
DEVELOPMENT
    * MONALIZUMAB ADVANCED TO A PHASE 3 CLINICAL TRIAL IN COMBINATION WITH
CETUXIMAB IN IO-PRETREATED HEAD AND NECK CANCER PATIENTS; TRIGGERED $50
MILLION MILESTONE PAYMENT FROM ASTRAZENECA
    * US AND EU LUMOXITI COMMERCIALIZATION RIGHTS RETURNING TO ASTRAZENECA

Source text for Eikon:  ID:nGNE48pVkJ 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))